

Eff. Date: 10 February 2022 Version: 3.0 IFU: BS04

BrightDAB, substrate DAB (For use with HRP-labeled detection systems)

Instruction For Use

These instructions apply to the WellMed BrightDAB substrate.

- 1. Intended Use
- 2. Summary and explanation
- 3. Kit components
- 4. Availability
- 5. Usage
- 6. Recommended Staining Protocol
- 7. Control slides
- 8. Storage
- 9. Warnings and precautions
- 10. Troubleshooting
- 11. Reference

1: Intended Use

For in-vitro Diagnostic Use. WellMed BrightDAB substrate DAB is intended for use in immunohistochemistry.

2: Summary and explanation

WellMed BrightDAB substrate DAB (3,3'Diaminobenzidine) is a widely used chromogen for immunohistochemical staining and immunoblotting. When in the presence of peroxidase enzyme, DAB produces a brown precipitate that is insoluble in alcohol and xylene. This product comes in a two-component system consisting of a liquid stable DAB chromogen and DAB substrate buffer. DAB Solution A: Ready-to-Use Buffered H₂O₂.; DAB Solution B: Concentrated DAB solution. BrightDAB is a very stable and superior formulation of DAB. In some cases, antibodies titers may increase by two-fold. BrightDAB can be used both manually and on automated stainers.

The clinical interpretation of any staining or its absence should be determined by a qualified pathologist and complemented by morphologic studies; controls should be evaluated within the context of the patient's clinical history and/or other diagnostic tests.

3: Kit components

BrightDAB, substrate DAB; consists of two components:

- 1. DAB Solution A: Buffered H₂O₂ (Ready-to-Use)
- 2. DAB Solution B: Concentrated DAB solution

4: Availability

Catalog Number	Contents	Volume	
BS04-110	BrightDAB, substrate DAB		
	• Sub cat.no.: BS04-110A: DAB Solution A: Buffered H ₂ O ₂ (Ready-to-Use)	110 ml	
	Sub cat.no.: BS04-110B: DAB Solution B: Concentrated DAB solution	5 ml	

WellMed BV, 't Holland 31, 6921 GX Duiven, The Netherlands

+ 31 (0) 85 273 23 23 info@wellmed.nl

www.wellmed.nl

Page 1 of 2





BS04-500	 BrightDAB, substrate DAB Sub cat.no.: BS04-500A: DAB Solution A: Buffered H₂O₂ (Ready-to-Use) Sub cat.no.: BS04-500: DAB Solution B: Concentrated DAB solution 	500 ml 22 ml
BS04-999	 BrightDAB, substrate DAB Sub cat.no.: BS04-999A: DAB Solution A: Buffered H₂O₂ (Ready-to-Use) Sub cat.no.: BS04-999B: DAB Solution B: Concentrated DAB solution 	1000 ml 45 ml

5: Usage

- 1 Working solution: Add 40 μ I DAB Solution B (± one drop) to 1 ml Solution A, mix well.
- 2 Incubate the DAB solution one time 8 minutes without washing in between.

6: Recommended Staining Protocol

Step	Reagent	Template step	Incubation time
1	Deparaffinize and rehydrate tissue section	Slide/tissue preparing	-
2	Wash aqua dest	Wash	2x 5 min
3	If applicable; HIER or digestive enzyme	Pre-treatment	*
4	Wash buffer	PBS or TBS buffer	2x 5 min
5	H ₂ O ₂ (concentration 3%)	Tissue preparing	10 min
6	Wash buffer	PBS or TBS buffer	2x 5 min
7	Primary antibody	Antibody	30 min
8	Wash buffer	PBS or TBS buffer	2x 5 min
9	Detection system, polymer HRP	Labeled polymer	30 min
10	Wash buffer	PBS or TBS buffer	2x 5 min
11	Substrate	DAB	8 min
12	Wash aqua dest	Wash	2x 2 min
13	Counterstain, dehydrate and coverslip	Auxiliary	-

* See applicable IFU

7: Control slides

A positive control, negative control and reagent control are needed and processed in the same way as the unknow specimen slide to interpret staining results.

8: Storage

Store at 2-8 °C and in the dark. Do not use after expiration date.

9: Warnings and precautions

Refer to SDS.

10: Troubleshooting

Please contact WellMed by phone or by email.

11: Reference

1) Shan-Rong Shi, James Guo, Richard J. cote, Lillian Young, Debra Hawes, Yan Shi, Sandra Thu and Clive R. Taylor, Applied Immunohistochemistry & Molecular Morphology, vol 7,201-208,1999

WellMed BV, 't Holland 31, 6921 GX Duiven, The Netherlands

+ 31 (0) 85 273 23 23

<mark>⊠ info@wellmed.nl</mark>

www.wellmed.nl

Page 2 of 2

